Goldman Sachs analyst David Roman raised the firm’s price target on LivaNova (LIVN) to $73 from $66 and keeps a Neutral rating on the shares. LivaNova delivered another year of double-digit revenue growth in 2025, reinforcing its medium-term plan and supporting 6%-7% organic growth guidance for 2026, though tailwinds from the Essenz upgrade cycle and Oxygenator gains appear to be peaking, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN: